Form D · Biotechnology
Acumen Pharmaceuticals, Inc.
Livermore, CA · CIK 0001576885
Offering snapshot reported May 15, 2013 · SEC filing
- Reported sold
- $700K Offering amount: $700K
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 18, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2013 | Initial | $700,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-196499
Source: Form D, filed May 15, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William F. Goure | Executive |
| Franz Hefti | Director, Promoter |
| Grant Krafft | Director |
| Mark Lampert | Director |
| Daniel J. O'connell | Director, Executive |
| David W. Summa | Director |
| Jurgen Weber | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4435 North First Street, Suite 360
Livermore, CA, 94551
Livermore, CA, 94551